Royal Bank of Canada Reaffirms Outperform Rating for Atyr PHARMA (NASDAQ:ATYR)

Royal Bank of Canada reiterated their outperform rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a research note published on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has a $16.00 target price on the stock.

Separately, HC Wainwright reissued a buy rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Thursday, August 1st.

Atyr PHARMA Trading Down 4.5 %

Shares of ATYR opened at $1.91 on Wednesday. The firm has a market capitalization of $131.81 million, a price-to-earnings ratio of -2.12 and a beta of 1.25. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07. Atyr PHARMA has a 52 week low of $1.08 and a 52 week high of $2.50.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. Research analysts anticipate that Atyr PHARMA will post -0.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Atyr PHARMA

In related news, Director Paul Schimmel acquired 52,300 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The stock was bought at an average price of $1.93 per share, for a total transaction of $100,939.00. Following the acquisition, the director now directly owns 413,023 shares of the company’s stock, valued at $797,134.39. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.70% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.